Physician profile
Fernando Sorto
NPI 1063705788
$1,210.30
in general payments reported to CMS, 2019-2025
19 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.53 · 2021: $60.30 · 2023: $128 · 2024: $614 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.15 | 2023-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $141.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $126.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $124.01 | 2024-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $91.48 | 2024-2025 | Prolastin-C Liquid |
| Insmed, INC. | $77.86 | 2024-2025 | Arikayce |
| Boston Scientific Corporation | $60.30 | 2021 | |
| Amgen INC. | $57.37 | 2024-2025 | Tezspire |
| Gilead Sciences, INC. | $52.71 | 2023-2024 | Veklury |
| Alk-Abello, INC | $43.21 | 2024 | Grastek, Odactra, Ragwitek |
| Mylan Specialty L.P. | $36.38 | 2024 | Yupelri |
| Harmony Biosciences LLC | $36.16 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $28.93 | 2023-2024 | Tezspire |
| Merck Sharp & Dohme LLC | $27.45 | 2024 | Winrevair |
| Vifor Pharma, INC. | $25.48 | 2024 | Zemaira |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $24.47 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $23.83 | 2019 | |
| Abbvie INC. | $23.35 | 2024 | |
| Viatris Specialty LLC | $17.80 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Sorto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.